Lexeo Therapeutics Files Proxy Materials
Ticker: LXEO · Form: DEFA14A · Filed: Jun 5, 2025 · CIK: 1907108
| Field | Detail |
|---|---|
| Company | Lexeo Therapeutics, Inc. (LXEO) |
| Form Type | DEFA14A |
| Filed Date | Jun 5, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: proxy-statement, regulatory-filing
TL;DR
Lexeo Therapeutics filed proxy docs, standard shareholder stuff.
AI Summary
Lexeo Therapeutics, Inc. is filing a Definitive Additional Materials proxy statement on June 5, 2025. This filing relates to the company's proxy materials and is being made under the 1934 Securities Exchange Act. The company's principal executive offices are located at 345 Park Avenue South, Floor 6, New York, NY 10010.
Why It Matters
This filing is a standard regulatory requirement for public companies to provide shareholders with information regarding upcoming meetings and voting matters.
Risk Assessment
Risk Level: low — This filing is a routine proxy statement, not indicating any immediate financial or operational risks.
Key Players & Entities
- Lexeo Therapeutics, Inc. (company) — Registrant
- 0000950170-25-082440 (filing_id) — Accession Number
- 20250605 (date) — Filing Date
- 345 PARK AVENUE SOUTH (address) — Company Address
FAQ
What type of filing is this?
This is a Definitive Additional Materials filing (DEFA14A) under the Securities Exchange Act of 1934.
Who is the filing company?
The filing company is Lexeo Therapeutics, Inc.
When was this filing made?
The filing was made on June 5, 2025.
What is the company's business address?
The company's business address is 345 Park Avenue South, Floor 6, New York, NY 10010.
What is the SIC code for Lexeo Therapeutics?
The Standard Industrial Classification (SIC) code for Lexeo Therapeutics is 2836, which corresponds to Biological Products (No Diagnostic Substances).
Filing Details
This Form DEFA14A (Form DEFA14A) was filed with the SEC on June 5, 2025 regarding Lexeo Therapeutics, Inc. (LXEO).